Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRXNASDAQ:CBAYNASDAQ:GALTNASDAQ:SBBPNASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsGALTGalectin Therapeutics$2.16-0.7%$1.64$0.73▼$3.90$137.98M0.7412,302 shs239,497 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsSVRASavara$2.14+1.7%$2.58$1.89▼$5.11$378.51M0.311.27 million shs1.11 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics0.00%-7.51%+68.36%+63.26%+0.23%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%SVRASavara0.00%-3.39%-14.26%-25.09%-50.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGALTGalectin Therapeutics1.6646 of 5 stars3.50.00.00.02.81.70.0SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.8094 of 5 stars3.31.00.00.00.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/ACBAYCymaBay Therapeutics 0.00N/AN/AN/AGALTGalectin Therapeutics 3.00Buy$6.00178.42% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ASVRASavara 2.60Moderate Buy$5.60162.30% UpsideCurrent Analyst Ratings BreakdownLatest ACRX, SBBP, SVRA, CBAY, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/29/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$6.00 ➝ $2.005/28/2025SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.005/28/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $8.005/28/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ASBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ASVRASavara-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)Latest ACRX, SBBP, SVRA, CBAY, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025SVRASavara-$0.12-$0.12N/A-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04CBAYCymaBay TherapeuticsN/A10.9610.96GALTGalectin TherapeuticsN/A0.080.08SBBPStrongbridge Biopharma0.383.002.95SVRASavara0.2014.9114.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%CBAYCymaBay Therapeutics95.03%GALTGalectin Therapeutics11.68%SBBPStrongbridge Biopharma52.03%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%CBAYCymaBay Therapeutics7.00%GALTGalectin Therapeutics50.10%SBBPStrongbridge Biopharma5.10%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSVRASavaraN/A172.84 million163.63 millionOptionableACRX, SBBP, SVRA, CBAY, and GALT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJuly 2 at 10:00 AM | prnewswire.comSavara Inc. (NASDAQ:SVRA) Receives $7.17 Average Price Target from AnalystsJune 28, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 27, 2025 | prnewswire.comSavara Independent Director Acquires 177% More StockJune 25, 2025 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from AnalystsJune 25, 2025 | marketbeat.comRichard J. Hawkins Purchases 48,225 Shares of Savara Inc. (NASDAQ:SVRA) StockJune 24, 2025 | insidertrades.comInsider Buying: Savara Inc. (NASDAQ:SVRA) Director Buys 48,225 Shares of StockJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 22, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 13, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 11, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 9, 2025 | accessnewswire.comAsavara elects board members and approves proposals at annual meetingJune 8, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 5, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 4, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRX, SBBP, SVRA, CBAY, and GALT Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.CymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Galectin Therapeutics NASDAQ:GALT$2.15 -0.02 (-0.69%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.15 0.00 (-0.23%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Savara NASDAQ:SVRA$2.13 +0.04 (+1.67%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.19 +0.06 (+2.81%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
